ClinicalTrials.gg
CompletedNCT00739349Updated Jun 6, 2016

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

A Phase 2 interventional study of NOVA22007 ''Cyclosporine'' and NOVA22007 ''Cyclosporine'' in Dry Eye, sponsored by Santen SAS. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-06.

Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Santen Pharmaceutical Co., Ltd..

Enrollment
8th of 12
132 · median 142
Started
2008
the only one that year
Phase 2
5 of 13
none open now
Registered
1st of 13
by date

Among the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd., this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2008, is one of 5 in phase 2, and was the 1st registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. is open now. The open studies under Dry Eye Syndromes, anywhere →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. as a file.
02

Study summary

Study is to assess the safety and efficacy of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions QD compared to vehicle for the treatment of the signs and symptoms of dry eye after a 3 month treatment period.

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Dry Eye
  • Cyclosporine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female 18 years and older
  • Diagnosis of dry eye in both eyes

Exclusion criteria

Exclusion Criteria:

  • to the use of the study medications
  • Known allergy or sensitivity to the study medications or their components
  • Female currently pregnant, nursing, or planning a pregnancy; or woman who has a positive pregnancy test
  • Have participated in an drug or device study within 30 days of Visit 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    1

    Cyclosporine 0.05%

    Drug: NOVA22007 ''Cyclosporine''

  • Experimental
    2

    Cyclosporine 0.1%

    Drug: NOVA22007 ''Cyclosporine''

  • Placebo comparator
    3

    vehicle/placebo

    Drug: vehicle/placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Assess the safety and efficacy of two doses of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Emulsions

    Time frame: Approximately 13 weeks

07

Study locations

1 site
  • Central Maine Eye Care, PA
    Lewiston, Maine 04240, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2008
First posted
Aug 21, 2008
Start
Aug 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results delay requested
Apr 29, 2015
Last update
Jun 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00739349
Lead sponsor
Santen SAS
Responsible party
Sponsor
First posted
Aug 21, 2008
Start date
Aug 2008
Primary completion
Jan 2009
Completion
Jan 2009
Last update
Jun 6, 2016

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NOVA22007

Start the discussion